{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:34:15Z","timestamp":1780450455084,"version":"3.54.1"},"reference-count":26,"publisher":"Georg Thieme Verlag KG","issue":"06","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Res (Stuttg)"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To detect the gender variations in adverse events (AEs) of voriconazole,\n                        promote personalised medicine.<\/jats:p><jats:p>A normalized dataset from Q1 2004 to Q4 2022 from the US Food and Drug\n                        Administration\u02bcs Adverse Event Reporting System (FAERS) was analyses. The\n                        reporting odds ratio (ROR), proportional reporting ratio (PRR), and P value\n                        were used to examine data from the FAERS database to detect risk signals and\n                        quantify the presence and extent of gender variations in voriconazole\n                        adverse events.<\/jats:p><jats:p>A total of 7670 cases (female\/male (2785\/4885)) of adverse reactions to\n                        voriconazole were analysed, and drug interaction (ROR 1.30 (1.10,1.54)),\n                        death and sudden death (ROR 1.31 (1.06,1.61)), actinic keratosis (ROR 1.98\n                        (1.10,3.57)) were found to be significantly more frequent in male patients\n                        than in female patients.<\/jats:p><jats:p>We found that gender was a determinant in voriconazole-related AEs using\n                        FAERS. Our results require future validation due to the inherent limits of\n                        this open data source, but they also identify potential contributing\n                        elements for a customised side effect profiling.<\/jats:p>","DOI":"10.1055\/a-2575-1530","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T22:40:46Z","timestamp":1745880046000},"page":"218-224","source":"Crossref","is-referenced-by-count":5,"title":["A Real-world Pharmacovigilance Study Of FDA Adverse Event Reporting\n                    System (FAERS) Events For Gender Of Voriconazole Drugs"],"prefix":"10.1055","volume":"75","author":[{"given":"Qiong","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanxi Bethune Hospital, Shanxi Academy of\n                    Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical\n                    University, Taiyuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanxi Bethune Hospital, Shanxi Academy of\n                    Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical\n                    University, Taiyuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanxi Bethune Hospital, Shanxi Academy of\n                    Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical\n                    University, Taiyuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanxi Bethune Hospital, Shanxi Academy of\n                    Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical\n                    University, Taiyuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanxi Bethune Hospital, Shanxi Academy of\n                    Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical\n                    University, Taiyuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyu","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanxi Bethune Hospital, Shanxi Academy of\n                    Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical\n                    University, Taiyuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Shanxi Bethune Hospital, Shanxi Academy of\n                    Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical\n                    University, Taiyuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1111\/jvim.15745","article-title":"ACVIM consensus statement guidelines for the classification, diagnosis, and\n                    management of cardiomyopathies in cats","volume":"34","author":"V Luis Fuentes","year":"2020","journal-title":"J Vet Intern Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: Fourth consensus report\n                    of the DLB Consortium","volume":"89","author":"I G McKeith","year":"2017","journal-title":"Neurology,"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016\n                    Update by the Infectious Diseases Society of America","volume":"63","author":"T F Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e13544","DOI":"10.1111\/ctr.13544","article-title":"Invasive Aspergillosis in solid-organ transplant recipients: Guidelines from the\n                    American Society of Transplantation Infectious Diseases Community of\n                    Practice","volume":"33","author":"S Husain","year":"2019","journal-title":"Clin Transplant"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s13318-019-00603-6","article-title":"Effect of Gender and Age on Voriconazole Trough Concentrations in Italian Adult\n                    Patients","volume":"45","author":"S Allegra","year":"2020","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1002\/jcph.2381","article-title":"Hypokalemia and Hyponatremia in Adult Patients Receiving Voriconazole\n                    Therapeutic Drug Monitoring","volume":"64","author":"L Cheng","year":"2024","journal-title":"J Clin Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1292163","DOI":"10.3389\/fphar.2024.1292163","article-title":"Clinical drug interactions between voriconazole and 38 other drugs: a\n                    retrospective analysis of adverse events","volume":"15","author":"B N Huo","year":"2024","journal-title":"Front Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.2147\/jpr.S473226","article-title":"Gabapentinoids-Related Delirium Adverse Events: A Real-World Study from 2004 to\n                    2022 Based on FAERS","volume":"17","author":"Z Nie","year":"2024","journal-title":"J Pain Res"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/1756-9966-30-93","article-title":"Hypersensitivity reactions to anticancer agents: data mining of the public\n                    version of the FDA adverse event reporting system, AERS","volume":"30","author":"K Kadoyama","year":"2011","journal-title":"J Exp Clin Cancer Res"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"E G Brown","year":"1999","journal-title":"Drug Saf"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/2041-1480-5-36","article-title":"Standardizing adverse drug event reporting data","volume":"5","author":"L Wang","year":"2014","journal-title":"J Biomed Semantics"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1109\/MITP.2005.122.","article-title":"RxNorm: prescription for electronic drug information exchange","volume":"7","author":"WM S Liu","year":"2005","journal-title":"IT Professional"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1197\/jamia.M3378","article-title":"MedEx: a medication information extraction system for clinical narratives","volume":"17","author":"H Xu","year":"2010","journal-title":"J Am Med Inform Assoc"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/4898082","article-title":"Gender Differences in Adverse Events of Ketamine Drugs: A Real-World Study Based\n                    on FAERS","volume":"2024","author":"J Zhang","year":"2024","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"A Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/pds.1058","article-title":"The history of disproportionality measures (reporting odds ratio, proportional\n                    reporting rates) in spontaneous reporting of adverse drug reactions","volume":"14","author":"N Moore","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1517\/14740338.2016.1167184","article-title":"Data mining spontaneous adverse drug event reports for safety signals in\n                    Singapore \u2013 a comparison of three different disproportionality measures","volume":"15","author":"P S Ang","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from\n                    spontaneous adverse drug reaction reports","volume":"10","author":"S J Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"4475","DOI":"10.1038\/s41598-023-27687-0","article-title":"Using disproportionality analysis to explore the association between periostitis\n                    and triazole antifungals in the FDA Adverse Event Reporting System Database","volume":"13","author":"H Li","year":"2023","journal-title":"Sci Rep"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/465688a","article-title":"Sex bias in trials and treatment must end","volume":"465","author":"A M Kim","year":"2010","journal-title":"Nature"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"24955","DOI":"10.1038\/srep24955","article-title":"Systematic Analysis of Adverse Event Reports for Sex Differences in Adverse Drug\n                    Events","volume":"6","author":"Y Yu","year":"2016","journal-title":"Sci Rep"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses\n                    improves efficacy and safety outcomes","volume":"46","author":"A Pascual","year":"2008","journal-title":"Clin Infect Dis"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1128\/aac.00702-11","article-title":"Population pharmacokinetics of voriconazole in adults","volume":"56","author":"W W Hope","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1093\/jac\/dku031","article-title":"Understanding variability with voriconazole using a population pharmacokinetic\n                    approach: implications for optimal dosing","volume":"69","author":"M J Dolton","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ijantimicag.2014.07.013","article-title":"Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised\n                    dosage regimens in patients with invasive fungal infections","volume":"44","author":"T Wang","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/s0149-2918(03)80126-1","article-title":"Voriconazole","volume":"25","author":"L Jeu","year":"2003","journal-title":"Clin Ther"}],"container-title":["Drug Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2575-1530.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T23:02:59Z","timestamp":1751670179000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2575-1530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":26,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2025,7,4]]},"published-print":{"date-parts":[[2025,7]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2575-1530","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2194-9379","2194-9387"],"issn-type":[{"value":"2194-9379","type":"print"},{"value":"2194-9387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]}}}